Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9441442 | 0.89 | HTR6 (0.46) | HTR6CA1CA2IDO1 | |
| SCHEMBL16242806 | 0.81 | HTR6 (0.57) | HTR6CA1CA2IDO1PDPK1 | |
| SCHEMBL731798 | 0.81 | HTR6 (0.61) | HTR6CA1CA2IDO1PDPK1 | |
| SCHEMBL2319101 | 0.81 | HTR6 (0.57) | HTR6CA1CA2IDO1PDPK1 | |
| SCHEMBL29207366 | 0.79 | HTR6 (0.55) | HTR6CA1CA2IDO1PDPK1 | |
| SCHEMBL11784556 | 0.78 | HTR6 (0.77) | HTR6CA1CA2IDO1PDPK1 | |
| SCHEMBL23832880 | 0.77 | HTR6 (0.53) | HTR6CA1CA2IDO1PDPK1 | |
| SCHEMBL20168950 | 0.76 | HTR6 (0.51) | HTR6CA1CA2IDO1PDPK1 | |
| SCHEMBL3243357 | 0.74 | HTR6 (0.50) | HTR6CA1CA2IDO1PDPK1 | |
| SCHEMBL11783908 | 0.73 | HTR6 (0.73) | HTR6CA1CA2PDPK1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5276031-A | Method for treating renal disease | ABBOTT LABORATORIES (US) | 1994-01-04 | — | — | US | claimed |
| US-5268374-A | Containing both amide and hydroxy groups | ABBOTT LABORATORIES (US) | 1993-12-07 | — | — | US | claimed |
| US-8598367-B2 | Nitrogen-containing heterocyclic compound and pest control agent | NIPPON SODA CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| US-20130137876-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PEST CONTROL AGENT | NIPPON SODA CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20110166358-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PEST CONTROL AGENT | NIPPON SODA CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
| EP-2332927-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PEST CONTROL AGENT | Nippon Soda Co., Ltd. (JP) | 2011-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137876-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PEST CONTROL AGENT | CBR3, CBR1, NOXO1 | HTR6 4280/4885CA1 1116/4885CA2 366/4885 |
| US-20110166358-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PEST CONTROL AGENT | CBR3, CBR1, NOXO1 | HTR6 4280/4885CA1 1116/4885CA2 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.